Jane Street’s Dianthus Therapeutics DNTH Stock Holding History

Jane Street’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,833	Closed	-$2.65M	–	11857
2025 Q4	$1.89M	Buy	+45,833	New	+$1.78M	﹤0.01%	4923
2024 Q4	–	Sell	-20,316	Closed	-$556K	–	9625
2024 Q3	$556K	Buy	+20,316	New	+$566K	﹤0.01%	7003
2024 Q2	–	Sell	-82,051	Closed	-$2.46M	–	9517
2024 Q1	$2.46M	Buy	82,051 +66,373	+423%	+$1.44M	﹤0.01%	3766
2023 Q4	$163K	Buy	+15,678	New	+$173K	﹤0.01%	8352

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Jane Street's DNTH Position: Q1 2026 in Review

Jane Street sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 45,833 shares — an estimated $2.65M sold.

Jane Street first reported a position in DNTH in Q4 2023 and held it in 4 quarters. The position peaked at $2.46M in Q1 2024. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Jane Street reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 45,833 Dianthus Therapeutics shares in Q1 2026, an estimated $2.65M.
Jane Street first reported a position in Dianthus Therapeutics in Q4 2023 and held it in 4 quarters.
Jane Street's Dianthus Therapeutics position peaked at $2.46M in Q1 2024.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.